AIP
CLYM

Ameritas Investment Partners’s Climb Bio CLYM Stock Holding History

Ameritas Investment Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,981
Closed -$3.64K – 3380
2025
Q1 		$3.64K Hold
2,981
– – ﹤0.01% 3025
2024
Q4 		$5.37K Hold
2,981
– – ﹤0.01% 3016
2024
Q3 		$15.2K Buy
2,981
+2,267
+318% +$16K ﹤0.01% 2773
2024
Q2 		$5.08K Buy
+714
New +$4.75K ﹤0.01% 3030
2022
Q2 		– Sell
-541
Closed -$5K – 3265
2022
Q1 		$5K Hold
541
– – ﹤0.01% 2976
2021
Q4 		$6K Hold
541
– – ﹤0.01% 3021
2021
Q3 		$10K Buy
+541
New +$11.2K ﹤0.01% 2947

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Ameritas Investment Partners's CLYM Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 2,981 shares — an estimated $3.64K sold.

Ameritas Investment Partners first reported a position in CLYM in Q3 2021 and held it in 7 quarters. The position peaked at $15.2K in Q3 2024. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,981 Climb Bio shares in Q2 2025, an estimated $3.64K.
  • Ameritas Investment Partners first reported a position in Climb Bio in Q3 2021 and held it in 7 quarters.
  • Ameritas Investment Partners's Climb Bio position peaked at $15.2K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.